Bioharvest Stock Price, News & Analysis

BioHarvest Sciences (NASDAQ: BHST), a pioneer in Botanical Synthesis technology, will present at the Canaccord Genuity 45th Annual Growth Conference from August 12-14, 2025, in Boston, Massachusetts.

CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and deliver a corporate presentation on Tuesday, August 12, 2025, at 11:00 a.m. Eastern time at the InterContinental Boston Hotel. The presentation will highlight the company's growth momentum across its consumer and CDMO businesses.

BioHarvest Sciences (NASDAQ: BHST) has launched VINIA DailyChews 2X Formula, a new product targeting athletes and active individuals. The chews contain 800mg of VINIA and 12mg of Piceid resveratrol, featuring a double dose of the company's proprietary red grape cell composition. The product has received Informed Sport certification, ensuring each batch is tested for banned substances, making it suitable for professional athletes and military personnel. The chews are designed to increase nitric oxide production, enhance blood flow, and improve oxygen delivery. Available in 30-count packs on VINIA.com, the product launch represents BioHarvest's expansion into the fitness segment of the nutraceuticals market. The company has also launched an international e-commerce platform enabling global orders in countries like the UK and Australia.

BioHarvest Sciences Inc. (NASDAQ: BHST) has secured a new CDMO (Contract Development and Manufacturing Organization) contract to develop a plant-based fragrance compound from a threatened plant species. The company will utilize its Botanical Synthesis technology platform and AI-assisted research capabilities for this project targeting the multi-billion-dollar fragrance market.

The Stage 1 contract focuses on developing cell banks for future production of targeted fragrance molecules, with milestone-based payments. Upon successful completion, Stage 2 would involve compound production in liquid media. This agreement expands BioHarvest's CDMO portfolio beyond pharmaceuticals and nutrition into the fragrance industry while contributing to rare plant species conservation.

BioHarvest Sciences (NASDAQ: BHST) reported strong Q1 2025 financial results, with revenue growing 47% year-over-year to $7.9 million, exceeding management guidance. Gross margins expanded to 58.5%, up 227 basis points. The company's VINIA® subscriber base surpassed 50,000 with $50M cumulative revenue since launch. Management projects Q2 2025 revenues of at least $8.5 million and expects to reach adjusted EBITDA breakeven in H2 2025. The company's CDMO division achieved significant milestones, completing Stage 1 development for a Nasdaq-listed pharmaceutical company contract. Despite revenue growth, the company reported a net loss of $2.3 million ($0.13 per share), improved from a $6.6 million loss in Q1 2024. Cash position stood at $3.4 million after raising $3.9 million in debt financing.

BioHarvest Sciences (NASDAQ: BHST) has successfully completed Stage 1 of its CDMO contract with an unnamed Nasdaq-listed pharmaceutical company and is advancing to Stage 2. The project, which began in early 2024, demonstrates the capability of BioHarvest's Botanical Synthesis platform to develop active pharmaceutical compounds.

In Stage 1, BioHarvest's research team successfully isolated target plant cells and replicated them using their proprietary platform. Stage 2 will focus on producing sufficient biomass for testing and developing optimal growing conditions in liquid media. Upon success, the project will progress to small and medium-scale production before moving to commercial volume production.

This milestone validates the platform's versatility and positions BioHarvest as a trusted partner in providing scalable, cost-effective alternatives to traditional compound sourcing for pharmaceutical, nutrition, and nutraceutical industries.

BioHarvest Sciences (NASDAQ: BHST), a pioneer in Botanical Synthesis technology, will release its Q1 2025 financial results on May 15, 2025, after market close. The company will host an investor conference call and webcast at 4:30 p.m. Eastern time on the same day.

Management will discuss quarterly results, provide a corporate update, and hold a Q&A session. The conference call can be accessed via U.S./Canada dial-in (1-877-300-8521) or International dial-in (1-412-317-6026) using Conference ID 2552254. A telephone replay will be available through May 29, 2025.

BioHarvest Sciences (NASDAQ: BHST) reported strong Q4 2024 financial results with revenues growing 62% to $7.3 million, exceeding guidance. Full-year 2024 revenues increased 99% to $25.2 million with gross margins expanding 1,000 basis points to 55%.

Key highlights include a CDMO partnership with Tate & Lyle for plant-based sweeteners development, successful Nasdaq Global Market uplisting, and VINIA® subscribers surpassing 50,000. The company launched VINIA® SuperFood tea line following successful coffee line introduction which generated $2.3 million since December 2023.

Q4 gross profit increased 80% to $4.1 million (56.7% margin), while marketing expenses decreased to 40.4% of revenue. Management projects Q1 2025 revenues of at least $7.8 million and expects adjusted EBITDA breakeven in H2 2025. The company ended Q4 with $2.4 million cash, subsequently raising $3.9 million in debt financing.

BioHarvest Sciences (NASDAQ: BHST) has scheduled its Q4 and full year 2024 earnings release for March 31, 2025, after market close. The company will host an investor conference call and webcast at 4:30 p.m. Eastern time on the same day.

The earnings call will include a discussion of financial results, corporate updates, and a Q&A session. Participants can join using U.S./Canada dial-in (1-844-825-9789) or International dial-in (1-412-317-5180) with Conference ID 10197712. A replay will be available through April 14, 2025, using pin number 10197712.

BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the 37th Annual Roth Conference, scheduled for March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors throughout the event.

The company, which pioneers the patented Botanical Synthesis technology platform, views this as a significant opportunity to showcase its growth trajectory. Following their Nasdaq listing and the launch of their CDMO Services Division, BioHarvest has achieved notable milestones, including:

• VINIA product reaching $50 Million in cumulative sales
• Advancement in CDMO Services division research for plant-based solutions
• Partnerships with pharmaceutical, nutraceutical, cosmetics, and nutrition sectors